Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of High-Dose Olamkicept in Healthy Men
NCT06298032Phase 1Completed
- Sponsor
- Ferring Pharmaceuticals
- Start
- Feb 2024
- Primary completion
- Nov 2024
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of olamkicept in inflammatory bowel disease (IBD) and ulcerative colitis (UC) (4 arms), sponsored by Ferring Pharmaceuticals. Primary endpoints: Treatment-Emergent Adverse Events up to 64 days, Change in Vital Signs at Day 64 and 2 more. Started Feb 2024; status: completed.
02
Drugs
olamkicept
03
Conditions
inflammatory bowel disease (IBD)ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT06298032.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06298032.